Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

12 Dec 2008 12:06

RNS Number : 0481K
Avacta Group PLC
12 December 2008
 



Avacta Group plc

Audited Results for the year to 31 July 2008

On 4 November 2008, Avacta Group plc ("Avacta", the "Group" or the "Company") announced its preliminary results for the year to 31 July 2008. The preliminary results included intangible assets of £7,144,000 and an other reserve of £1,834,000 reflecting the application of reverse acquisition accounting of the transaction whereby Avacta Limited reversed into Avacta Group plc (formerly Readybuy plc) during August 2006. Upon conversion from accounting under United Kingdom Generally Accepted Accounting Practice to International Financial Reporting Standards as adopted by the European Union, it is possible to recognise a different treatment of this transaction within the financial statements, which the Directors believe to be beneficial.

There is no impact on the income statement or the cash flows of the Group in either the current or comparative accounting period

Accordingly, the consolidated balance sheet of the Group has been adjusted from that included within the Preliminary Announcement to reflect this revised treatment resulting in goodwill of £3,563,000 that had been previously recognised within the intangible assets of £7,144,000 now being recognised within the other reserveThe adjusted consolidated balance sheet is included within this announcement. 

There are no other changes to the Preliminary Announcement.

The Company's full Annual Report & Accounts are available on its website at www.avacta.com

Enquiries:

Avacta Group plc

087 0835 4367

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Daniel Stewart & Company plc

020 7776 6550

Lindsay Mair / Charlotte Stranner

Novum Securities Limited

020 7562 4700

Henry Turcan

Haggie Financial LLP

020 7417 8989

Nicholas Nelson / Kathy Boate

   

   Consolidated Balance Sheet as at 31 July 2008

2008

2007

£000

£000

Non-current assets

Property, plant & equipment

290

148

Intangible assets

3,581

-

-------------

------------

3,871

148

-------------

------------

Current assets

Trade and other receivables

92

170

Income taxes

84

-

Cash and cash equivalents

1,097

2,527

-------------

------------

1,273

2,697

-------------

------------

Total assets

5,144

2,845

-------------

------------

Current liabilities

Trade and other payables

(234)

(164)

Finance lease obligations

(11)

(11)

-------------

------------

(245)

(175)

-------------

------------

Non-current liabilities

Finance lease obligations

(30)

(41)

-------------

------------

(30)

(41)

-------------

------------

Total liabilities

(275)

(216)

-------------

------------

Net assets

4,869

2,629

-------------

------------

Equity attributable to equity holders of the Company

Called up share capital

900

856

Share premium account

6,524

4,882

Other reserve

(1,729)

(1,729)

Capital reserve

1,899

-

Retained earnings

(2,725)

(1,380)

-------------

------------

Total equity

4,869

2,629

-------------

------------

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EAAAAFEDPFFE
Date   Source Headline
19th Jul 20163:13 pmRNSHolding(s) in Company
19th Jul 20167:15 amRNSHardman report: New Affimer opportunities
14th Jul 20167:00 amRNSCollaboration with Glythera
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20167:00 amRNSAffimer Binders for Zika Virus Diagnostics
16th Jun 201611:08 amRNSIssue of Equity
13th Jun 20167:00 amRNSCollaboration with Mologic
29th Apr 20163:04 pmRNSDirector's Dealing
25th Apr 20167:00 amRNSHalf-year Report
19th Apr 20167:00 amRNSAffimer Therapeutic Platform Development Milestone
7th Apr 20167:00 amRNSDirector's Dealing
5th Apr 20167:00 amRNSInvestor Evening
15th Mar 20167:00 amRNSIssue of Equity
7th Mar 20167:00 amRNSAvacta Establishes Scientific Advisory Board
25th Feb 20164:34 pmRNSHolding(s) in Company
24th Feb 20167:00 amRNSGrant Funding Awarded
23rd Feb 201610:54 amRNSHardman & Co Issues Research Report
23rd Feb 20167:00 amRNSDirector's Dealing
17th Feb 20167:00 amRNSDirectors' Dealings and Issue of Equity
26th Jan 20168:05 amRNSShare Consolidation
25th Jan 20163:35 pmRNSResult of Annual General Meeting
25th Jan 20167:01 amRNSPre-close trading update
25th Jan 20167:00 amRNSPhilippe Cotrel Appointed Chief Commercial Officer
21st Jan 20167:00 amRNSProposed Shareholder Consolidation
7th Jan 20167:00 amRNSPosting of Annual Report & Accounts and AGM Notice
5th Jan 20167:00 amRNSIssue of Equity
10th Dec 20157:00 amRNSAppointment of Tony Gardiner as CFO
1st Dec 20154:44 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSIssue of Equity
23rd Nov 20157:00 amRNSIssue of Equity
6th Nov 201510:56 amRNSHolding(s) in Company
30th Oct 20157:00 amRNSIssue of Equity
26th Oct 20157:00 amRNSFinal Results
19th Oct 20157:00 amRNSAffimers improve disease resistance in plants
9th Oct 20157:00 amRNSRobust performance of Affimers on Luminex platform
8th Oct 20157:00 amRNSNotice of Results
17th Sep 20157:00 amRNSAppoints Dr Mike Owen as Non-executive Director
10th Sep 20157:00 amRNSTotal Voting Rights
3rd Sep 20157:00 amRNSIssue of Equity
5th Aug 201510:00 amRNSHolding(s) in Company
5th Aug 20157:00 amRNSHolding(s) in Company
4th Aug 201510:18 amRNSIssue of Equity
31st Jul 201510:42 amRNSResult of General Meeting
23rd Jul 20157:00 amRNSIssue of Equity
15th Jul 20157:00 amRNSConditional Placing to Raise up to £22.0 Million
7th Jul 20158:00 amRNSBoard Change
7th Jul 20157:00 amRNSPre-Close Trading Update
20th May 201511:48 amRNSHolding(s) in Company
19th May 201512:42 pmRNSHolding(s) in Company
11th May 20157:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.